27.07.2011 • NewsQ2 2011sales and profitsPraxair

Praxair Q2 Profit Rises

Praxair Wednesday said net income in the second quarter increased to $425 million or $1.38 per share from $371 million or $1.19 per share in the prior year.

On average, 16 analysts polled by Thomson Reuters expected the company to earn $1.37 per share in the quarter. Analysts' estimates typically exclude special items.

Sales increased 13% to $2.86 billion from $2.53 billion, surpassing Wall Street view of $2.79 billion.

For the third quarter, Praxair expects earnings per share in the range of $1.35 to $1.40. Analysts expect earnings of $1.39 per share for the quarter.
Further, the company increased its full year earnings guidance to $5.40 to $5.50 per share from the prior range of $5.35 to $5.45.

For 2011, Praxair expects sales in the area of $11.2 billion. The previous projection was for sales in the area of $11 billion.

Wall Street expects 2011 earnings of $5.47 per share on revenues of $11.16 billion.

 

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.